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Abstract 
Blood transfusion is a common 
procedure that usually goes without 
complications. However, adverse 
transfusion reactions should not be 
overlooked.  Transfusion-related acute lung 
injury (TRALI) is the leading cause of 
transfusion-related fatalities and is 
characterized by the onset of acute 
respiratory distress in the form of non-
cardiogenic pulmonary oedema. We hereby 
report the case of a 28 year old Jamaican 
lady who developed acute onset dyspnoea, 
tachycardia and hypoxaemia following 
transfusion of fresh frozen plasma and red 
cell concentrates. 
Introduction 
TRALI is the leading cause of 
transfusion-related mortality and it often 
remains unrecognized clinically.1 The true 
incidence of TRALI is unknown because of 
the difficulty in making the diagnosis and 
under-reporting especially in the intensive 
care setting where the development of 
symptoms may be attributed to multiple 
other disease processes or therapeutic 
interventions rather than transfusion.  It is 
estimated to occur in 1:1300 to 1:5000 
transfusions of plasma-containing blood 
products.2 Though uncertainty remains with 
regards to the pathophysiology of TRALI, 
its development is influenced by both 
transfusion-related and patient-related risk 
factors. 
Case Report 
A 28-yr old, previously healthy woman, 
presented to the Accident and Emergency 
department complaining of lower abdominal 
pain.  A Focused Assessment with 
Sonography in Trauma (FAST) scan showed 
free fluid in the pelvis and she was 
subsequently diagnosed with a ruptured 
ovarian cyst.  Laboratory investigations on 
presentation showed a white cell count of 
6.3 x 109/L, haemoglobin of 7.8g/dL 
(normal mean corpuscular volume and mean 
corpuscular haemoglobin) and a platelet 
count of 166 x 109/L. Liver and renal 
function, glucose and coagulation screen 
were within normal limits.  She underwent 
urgent laparoscopic ovarian cystectomy and 
was transfused four units of packed red cells 
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(PRCs) intra-operatively.  In view of 
significant intra-operative bleeding she 
required further transfusion with fresh 
frozen plasma (FFP).  However, whilst 
receiving her fourth unit of FFP, she became 
acutely dyspnoeic.  On examination she had 
low-grade fever, tachycardia (145bpm) and 
tachypnoea with a respiratory rate of 25 
breaths/minute and an oxygen saturation of 
77% on room air.  On auscultation of the 
chest, there was decreased air entry both 
bases with left basal crepitations.  The rest 
of her physical examination was 
unremarkable. 
CXR showed bilateral patchy 
infiltration particularly in the left lung field 
(Figure 1). 
Figure 1: AP CXP showing bilateral lung infiltrates 
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The patient was diagnosed with 
transfusion-related acute lung injury and 
required admission to intensive care for 
ventilatory and haemodynamic support.  The 
patient did not require intubation as she 
improved significantly with non-invasive 
ventilation.   
Repeat laboratory investigations 
showed a transient leukopenia (white cell 
count of 3.4 x 109/L) followed by a 
leucocytosis (white cell count of 12.3 x 
109/L) within 24 hours of her transfusion. 
In view of leukopenia and the presence 
of infiltrates on chest x-ray, blood cultures 
were taken and she was also started on 
piperacillin/tazobactam to cover for any 
potential concomitant infectious pathology.  
The patient stabilised and made an 
uneventful recovery within a few days. 
Definition of TRALI 
TRALI has been defined by both the 
National Heart, Lung, and Blood Institute 
(NHLBI) working group as well as a 
Canadian Consensus Conference, as new 
acute lung injury (ALI)/acute respiratory 
distress syndrome (ARDS) occurring during 
or within six hours after blood product 
administration characterised by acute 
hypoxaemia, bilateral infiltrates on frontal 
chest radiograph and no evidence of 
circulatory overload/left atrial hypertension 
or pre-existing ALI/ARDS before 
transfusion.1,3 
Pathogenesis 
TRALI is postulated to develop as the 
result of two separate clinical events.  The 
first or priming event is due to the patient's 
primary disease or condition, which results 
in activation of the pulmonary endothelium 
and the accumulation of primed, adherent 
neutrophils in the lung.  The second event is 
the subsequent blood transfusion, whereby 
the primed neutrophils are activated by 
either a leucocyte antibody or biological 
response modifiers (BRM) present in the 
transfused blood product.  Activation of the 
primed neutrophils results in augmented 
release of their microbicidal arsenal, which 
causes collateral injury to the pulmonary 
endothelium that manifests as capillary leak, 
and clinically as TRALI.  Thus, the two-
event mechanism proposes that both 
recipient and blood product factors 
contribute to TRALI pathogenesis.4 
Risk Factors 
All blood components have been 
implicated in TRALI; however, plasma 
containing blood components are most 
commonly implicated, with FFP and whole 
blood-derived platelet concentrates (WB-
PLTs) having caused the largest number of 
reported cases.  In most centres, the plasma 
is platelet-rich plasma.  This use of platelet-
rich plasma is significant for it allows for 
the infusion of platelet fragments and all 
endogenous growth factors and other 
mediators which are platelet-derived.  Many 
of these compounds are effective activators 
of polymorphonuclear cells and innate 
immunity resulting in acute lung injury. 
Certain patient risk factors have been 
identified as increasing the risk of TRALI.5
These include: 
• Higher IL-8 levels – may prime
neutrophils and the lung endothelium6
• Shock – results in tissue injury
possibly predisposing to TRALI
through priming of the recipient’s
endothelium and immune cells7
• Liver surgery5
• Positive fluid balance – more likely to
manifest pulmonary oedema when
there is ALI8
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• Peak airway pressure greater than
30cm of H2O if mechanically
ventilated before transfusion –
increases the risk of ALI9-10
• Chronic alcohol abuse – results in
lower levels of glutathione antioxidant
in the lung11-12
• Current smoking9-10
Pearl Toy et al reported that receipt of
plasma (including whole blood) from female
donors is a strong risk factor, and reduction
of this risk factor was concurrent with a
decrease in TRALI incidence from
approximately 1:4000 units to 
approximately 1:12000 units.5,13 
Furthermore, there is evidence that TRALI 
is commoner in recipients of blood products 
from multiparous female donors who are 
more likely to possess anti-HLA antibodies 
and anti-neutrophil-specific antibodies with 
increasing number of pregnancies.14 
Following a case analysis, it was 
established that our patient had received 
blood products from ten different donors, 
three of which were females.  Out of the 
female donors, one was nulliparous whilst 
the other two donors had a history of three 
or more gestations.  Antibody testing of 
recipient and donor blood concluded that the 
donor with HLA antibodies with the same 
specificity as that of our patient was one of 
the multiparous females.  This is in keeping 
with the literature data that suggests a higher 
risk of TRALI when receiving blood 
products from multiparous females. 
The association between the risk of 
TRALI and blood product storage time has 
been debated for long.  Whether longer RBC 
storage is associated with increased risk for 
lung injury and mortality is considered the 
most critical issue currently facing 
transfusion medicine.  In a prospective case-
control study by Toy et al (2012), evidence 
against longer storage of leuko-reduced 
RBC units being an important risk for 
TRALI was documented.5,15 There is also 
conflicting data regarding the risk of TRALI 
with multiple transfusions.  Results from the 
same case-control study by Toy et al had 
initially suggested increased risk for TRALI 
with increasing numbers of transfusions.  
However, when a multivariate analysis was 
carried out, no statistically significant 
correlation was found.5 
Diagnosis and Management 
TRALI occurs within 6 hours of 
transfusion with the majority of cases 
presenting during the transfusion or within 
the first 2 hours. TRALI is the insidious 
onset of acute pulmonary insufficiency 
presenting as tachypnoea, cyanosis, and 
dyspnoea with acute hypoxaemia, 
PaO2/FiO2<300 mmHg, and decreased 
pulmonary compliance, despite normal 
cardiac function. 
Although the diagnosis is mainly based 
on clinical grounds, certain laboratory and 
radiographic investigations can facilitate the 
diagnostic challenge posed by TRALI.14 
Radiographic examination reveals diffuse, 
fluffy infiltrates consistent with pulmonary 
oedema. 
Transient leukopenia has been 
temporally associated with the onset of 
TRALI (as in our case report), and serial 
measurements of white cell count may 
reveal this finding.16,17  
Echocardiography, measurement of 
BNP levels and pulmonary oedema fluid 
protein analysis are complementary tests in 
helping to exclude cardiac dysfunction and 
volume overload as the cause of the acute 
symptomatology.5,16 
As previously discussed, the precise 
mechanism responsible for TRALI is 
unknown, but the syndrome has been 
associated with passive transfer of leukocyte 
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antibodies and biologically active lipids in 
blood components.  The majority of cases of 
TRALI (65-80%) are thought to be triggered 
by passive transfer of HLA Class I and/or 
neutrophil-specific antibodies,18-22 or HLA 
Class II antibodies23,24 present in the plasma 
of the transfused blood product. In a 
minority of cases, the causative antibodies 
are present in the recipient, and react with 
transfused cellular material. Testing plasma 
samples from the implicated donor and 
patient for leukocyte antibodies can be very 
helpful in evaluation of a suspected TRALI 
case, however these are not found in all 
cases of TRALI.5 
Toy et al found no evidence of TRALI 
after transfusion of blood products from one 
donor with multiple HLA antibodies into 
103 recipients, 25% of whom had ≥1 HLA 
antigen that matched the donor antibody.25 
On the other hand, Kopko et al reported the 
presence of a mild to severe respiratory 
syndrome in 35% of recipients receiving 
blood products from a donor with anti-  
human-neutrophil-antigen (HNA)-3a 
antibody. Therefore, a case of TRALI may 
represent an isolated event, but donor 
granulocyte antibodies rather than HLA 
antibodies seem likely to cause multiple 
cases of TRALI.18 
As with other forms of ALI/ARDS, 
there is no significant treatment for TRALI.  
If the patient is still being transfused when 
the diagnosis is first suspected, the 
transfusion should be stopped immediately.  
The treatment for TRALI is supportive and 
consists of aggressive respiratory support 
with supplemental oxygen and mechanical 
ventilation, if required, at low enough 
pressure and tidal volume to not induce 
barotraumas.26-27 In rare cases, the 
hypoxemia resulting from TRALI can be so 
severe that extracorporeal oxygenation may 
be required as a temporizing measure while 
the lungs heal.28,29 It is important to report 
any case of TRALI to the blood service so 
that an implicated donor can be contacted 
and, if appropriate, taken off the donor 
panel.5 
Risk reduction strategies: 
Different centres have adopted different 
strategies ranging from testing of allo-
exposed donors for leucocyte antibodies to 
the exclusion of all females from donating 
high plasma volume products. Another 
strategy involves dilution of antibodies 
present by pooling of plasma donations of 
multiple donors. From a bedside view, the 
most important measure to prevent TRALI 
is to limit patients' exposure to allogenic 
blood products. Furthermore, recognition 
and awareness of the syndrome need to be 
heightened among clinicians.8
Conclusion 
TRALI has been reported by 
haemovigilance programs to be the most 
frequent cause of transfusion-related 
mortality in the US and a leading cause of 
transfusion-related morbidity and mortality 
elsewhere.  TRALI is thought to be under-
diagnosed and under-reported, particularly 
in critical care setting where the 
development of symptoms may be attributed 
to multiple other disease processes or 
therapeutic interventions rather than 
transfusion.  Thus, maintaining a high index 
of suspicion is crucial in making the correct 
diagnosis, especially when transfusing 
patients using fresh frozen plasma and 
whole blood-derived platelet concentrates. 
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